Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Insertion of the selection cassette in exon2.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-EPS8L2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
EPS8L2 also known as Epidermal Growth Factor Receptor Substrate 8-Like Protein 2 plays a mechanical role in cellular signaling and cytoskeletal organization. This protein has a molecular mass of approximately 97 kDa. EPS8L2 expresses in various tissues including the brain liver and testis where it contributes to diverse cellular processes. Its structural components include actin-binding domains which allow interaction with the cytoskeleton and other signaling molecules.
Biological function summary
EPS8L2 regulates actin cytoskeleton dynamics and signal transduction pathways. It is part of the EPS8 family of proteins and functions within a complex to mediate cell shape and movement. This protein acts as a scaffold that facilitates interactions among actin filaments and other proteins which influences cell migration and invasion. EPS8L2 modifies actin-related changes that are essential in dynamic cellular environments.
Pathways
EPS8L2 integrates into the EGFR (Epidermal Growth Factor Receptor) signaling pathway influencing cellular growth and differentiation. In another role it participates in the MAPK/ERK pathway by interacting with components like GRB2 and SOS1. These pathways control various aspects of cell behavior impacting cell proliferation and survival. Related proteins such as EPS8 also share similar pathway interactions and have overlapping functions in cellular signaling.
EPS8L2 connects to cancer and neurodegenerative diseases. In cancer dysregulation of EGFR signaling involving EPS8L2 may contribute to tumor progression and metastasis. The protein's interactions influence cellular behaviors critical to cancer development. In neurodegenerative disorders alterations in cytoskeletal dynamics associated with EPS8L2 may exacerbate conditions like Alzheimer's Disease. This protein interacts with others like ApoE impacting pathways linked to neuronal health and degeneration.
